Bloomberg -- Merck & Co., the second-largest U.S. drugmaker, reported third-quarter profit that rose more than analysts estimated as reduced costs helped overcome revenue losses from drugs facing generic competition.
Bloomberg -- Merck & Co., the second-largest U.S. drugmaker, reported third-quarter profit that rose more than analysts estimated as reduced costs helped overcome revenue losses from drugs facing generic competition.
